Motus GI Appoints Jeff Hutchison as VP of U.S. Sales and Commercial Operations
August 09 2018 - 8:35AM
Business Wire
– Hutchison brings extensive background in
innovative GI product sales and will lead development of commercial
organization in preparation for 2019 launch –
Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the
"Company"), a medical technology company dedicated to improving
clinical outcomes and enhancing the cost-efficiency of colonoscopy,
announced today the appointment of Jeff Hutchison as Vice President
of U.S. Sales and Commercial Operations. Mr. Hutchison will be
responsible for building Motus GI’s U.S. sales organization and
driving the Company’s pre-launch commercial activities ahead of the
planned launch of the Pure-Vu® System into the inpatient market in
2019. The Pure-Vu® System, the Company’s flagship, FDA-cleared
medical device system, enables physicians to rapidly cleanse the
colon during the colonoscopy procedure to facilitate improved
visualization and enable a quality exam. Challenges with bowel
preparation for inpatient colonoscopy represent a significant area
of unmet need that directly affects clinical outcomes and increases
the cost of care in a market segment that comprises approximately
1.5 million annual procedures in the U.S. and approximately 4
million annual procedures worldwide.
“The appointment of Jeff Hutchison as our VP of U.S. Sales and
Commercial Operations is a critical step in our strategic roadmap
to the commercial launch of the Pure-Vu® System in the inpatient
colonoscopy market,” commented Mark Pomeranz, CEO of Motus GI.
“Jeff is an experienced and senior sales leader in the GI space who
was a key player in the launch and commercial build out of BÂRRX
prior to its acquisition by Covidien as well as its continued
growth under Covidien and then Medtronic. He knows how to build and
lead a sales organization to drive new market opportunities in the
GI space and that is exactly why he is joining Motus GI now.”
Mr. Hutchison joins Motus GI following over 25 years of
executive sales leadership and new market development experience in
the medical device industry. He most recently served as Vice
President of U.S. Sales for Bio2 Medical. Prior to that, he served
as Area Vice President of Sales for Medtronic GI Solutions (NYSE:
MDT) where he led the Western Division of Medtronic’s GI business,
managed the integration of two major acquisitions and led the
growth of the organization from 33 territories and 4 regions to 135
territories and 18 regions. Previously, he served as Director of
U.S. Sales for BÂRRX Medical, where he led the U.S. sales
organization and drove commercialization of BÂRRX’s endoscopic
treatment devices for Barrett’s Esophagus. Mr. Hutchison was an
integral part of the BÂRRX’s acquisition team when it was purchased
by Covidien in 2011 (Covidien was later acquired by Medtronic).
During that time, he oversaw the hiring of 50 professionals. Prior
to BÂRRX, Mr. Hutchison spent 17 years at Boston Scientific (NYSE:
BSX) in a variety of sales, sales management and market development
roles in the endoscopy and cardiology divisions.
“The Pure-Vu® System presents an opportunity to deliver
significant clinical and economic benefits not only for patients
but for all stakeholders involved in colonoscopy for hospitalized
patients including physicians, nursing staff and hospital
administrators,” said Hutchison. “I am thrilled to be joining Motus
GI at this time when I can play a pivotal role in building our
commercial organization and driving our commercialization plan
focused on the inpatient hospital market. I am really looking
forward to bringing this product to market and seeing us realize
its potential.”
About Motus GI and the Pure-Vu® System
Motus GI Holdings, Inc. is a medical technology company, with
subsidiaries in the U.S. and Israel, dedicated to improving
clinical outcomes and enhancing the cost-efficiency of colonoscopy.
The Company’s flagship product is the Pure-Vu® System, a 510(k)
U.S. Food and Drug Administration cleared medical device indicated
to help facilitate the cleaning of a poorly prepared colon during
the colonoscopy procedure. The device integrates with standard
colonoscopes to enable cleaning during the procedure while
preserving standard procedural workflow and techniques. The
Pure-Vu® System has received CE mark approval in Europe. The
Pure-Vu® System is currently being introduced on a pilot basis in
the U.S. market, and the Company is planning to initiate a full
commercial launch focused on the inpatient colonoscopy market in
the U.S. and select international markets in 2019. Challenges with
bowel preparation for inpatient colonoscopy represent a significant
area of unmet need that directly affects clinical outcomes and
increases the cost of care in a market segment that comprises
approximately 1.5 million annual procedures in the U.S. and
approximately 4 million annual procedures worldwide. Motus GI
believes the Pure-Vu® System may improve outcomes and lower costs
for hospitals by reducing the time to successful colonoscopy,
minimizing delayed and aborted procedures, and improving the
quality of an exam. In clinical studies to date, the Pure-Vu®
System significantly increased the number of patients with an
adequate cleansing level, according to the Boston Bowel Preparation
Scale Score, a validated assessment instrument.
For more information, visit www.motusgi.com and connect with the
Company on Twitter, LinkedIn, Facebook and Google+.
Forward-Looking Statements
This press release contains certain forward-looking statements.
Forward-looking statements are based on the Company's current
expectations and assumptions. The Private Securities Litigation
Reform Act of 1995 provides a safe-harbor for forward-looking
statements. These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential," "predict," "project," "should," "would" and similar
expressions and the negatives of those terms, including without
limitation, risks inherent in the development and commercialization
of potential products, uncertainty in the timing and results of
clinical trials or regulatory approvals, maintenance of
intellectual property rights or other risks discussed in the
Company’s Form 10-K filed on March 28, 2018, and its other filings
with the Securities and Exchange Commission. Prospective investors
are cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date hereof. The Company
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180809005139/en/
Investors:Jenene Thomas
Communications, LLCJenene Thomas, 833-475-8247mots@jtcir.com
Motus GI (NASDAQ:MOTS)
Historical Stock Chart
From Apr 2024 to May 2024
Motus GI (NASDAQ:MOTS)
Historical Stock Chart
From May 2023 to May 2024